
USD $2242.08
Generic Name: Ruxolitinib
JAKAVI (Ruxolitinib) is a medication used for the treatment of certain conditions related to the immune system, including myelofibrosis and polycythemia vera. It belongs to a class of drugs known as Janus kinase (JAK) inhibitors, which work by blocking specific enzymes involved in the inflammatory process.
JAKAVI is indicated for the treatment of:
The recommended dosage of JAKAVI is tailored to the individual patient's needs and should be determined by a healthcare professional. It is typically taken twice daily, with or without food.
Ruxolitinib works by inhibiting the activity of JAK1 and JAK2 enzymes, which play a crucial role in the signaling pathways of various cytokines involved in hematopoiesis and immune response. By blocking these enzymes, JAKAVI helps reduce inflammation and control symptoms associated with myelofibrosis and polycythemia vera.
Common side effects of JAKAVI may include:
Patients should consult their healthcare provider for a comprehensive list of potential side effects and to discuss any concerns.
JAKAVI may interact with other medications. It is essential to inform your healthcare provider about all other medications you are taking to avoid potential interactions.
Store JAKAVI at room temperature, away from moisture and heat. Keep out of reach of children.
JAKAVI (Ruxolitinib) is a vital treatment option for patients with specific blood disorders. Always follow your healthcare provider's instructions regarding the use of this medication.